Preparation method and application of carboxylic acid and derivative thereof
By developing carboxylic acid derivatives that can inhibit nNOS-SERT coupling, the problem of slow onset of existing antidepressants and many side effects has been solved, and rapid and effective treatment of depression is achieved, especially in the symptoms of loss of interest. improve.
Patent Information
- Application Number
- CN202410932778.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-05
AI Technical Summary
Existing antidepressants have slow onset, many side effects and low efficiency, which cannot effectively treat the symptoms of loss of interest in patients with depression. Drugs that take effect quickly, such as ketamine, have side effects such as addiction and somatic separation.
A class of carboxylic acids and their derivatives have been developed that can inhibit the coupling of nNOS-SERT, thereby quickly exerting an antidepressant effect and avoiding the side effects of traditional antidepressants.
This carboxylic acid derivative can take effect quickly, significantly inhibit the symptoms of loss of interest in patients with depression, and avoid side effects such as addiction and somatic separation, providing a new rapid antidepressant treatment plan.
Smart Images

Figure CN118894776A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the pharmaceutical field and provides a class of carboxylic acids and their derivatives, and preparation methods and applications thereof. Specifically, a class of carboxylic acids and their derivatives that can inhibit nNOS-SERT coupling and have rapid antidepressant effects. Background Art
[0002] Depression is a common mental disorder, which is mainly manifested by low mood, loss of interest, and loss of pleasure. Some serious patients may also experience anxiety, self-blame, and suicide attempts. According to a study by the World Health Organization, about 300 million people will suffer from major depression at some time in their lives. Suicide is the most serious problem of depression, and its incidence rate accounts for about 15% of patients with depression.
[0003] Currently, antidepressants based on serotonin (5-HT) in clinical practice generally have the disadvantages of slow onset of action (requiring 3 to 4 weeks to take effect), many side effects, and low effectiveness (about 40% of patients are ineffective); although ketamine has a rapid onset of action, it has side effects such as addiction and somatic dissociation. Therefore, new antidepressants with rapid onset of action and fewer side effects are clinically needed.
[0004] The coupling of neuronal nitric oxide synthase (nNOS) and 5-hydroxytryptamine transporter (SERT) is a new antidepressant target discovered by the inventor of this patent (Science, 2022, 378, 390-398). Inhibiting the coupling of nNOS-SERT can promote the expression of SERT on the cell membrane, reduce the concentration of 5-hydroxytryptamine (5-HT) outside the DRN brain region, and avoid 5-HT 2A The negative feedback regulation of R receptors promotes neuronal discharge, thus exerting a rapid antidepressant effect. Since the coupling of nNOS-SERT has a specific distribution in the DRN brain region and does not affect the functions of uncoupled nNOS and SERT, it can avoid many side effects of current clinical monoamine neurotransmitter antidepressant drugs, and will not induce addiction, dissociation of consciousness and other side effects like ketamine.
[0005] The forced swim test (FST), tail suspension test (TST) and sucrose preference test (SPT) are widely used to detect the core symptoms of depression in mice - despair and anhedonia. Loss of interest is another core and common symptom in patients with depression. Developing compounds targeting loss of interest in depression has broad application prospects.
[0006] This patent provides a class of carboxylic acids and their derivatives, which can inhibit the coupling of nNOS-SERT and play a therapeutic role in depression and loss of interest caused by depression. Summary of the invention
[0007] The invention provides a class of carboxylic acids and derivatives thereof, and application thereof in inhibiting the nNOS-SERT coupling effect to play a rapid antidepressant role in treating loss of interest in depression, and has broad application prospects.
[0008] The first object of the present invention is to provide carboxylic acids and derivatives thereof, which conform to the following general structural formula:
[0009]
[0010] X=C、OO;
[0011] n = 1 to 6;
[0012] R1, R2, and R3 are each independently selected from H, CH3, CF3, Et, n-Pr, i-Pr, cyclopropyl, cyclobutyl, cyclopentyl, Cl, and Br;
[0013] R4 = H, an alkyl group having 1 to 4 carbon atoms.
[0014] Further, the structural formula is any one of the following compounds:
[0015]
[0016]
[0017] Further, the structural formula is any one of the following compounds:
[0018]
[0019] Further preferably, the compound is
[0020] Most preferably, the compound is The second object of the present invention is to provide a pharmaceutical composition comprising the aforementioned compound or a pharmaceutically acceptable salt thereof.
[0021] Furthermore, the pharmaceutically acceptable salt is selected from sodium salt and potassium salt.
[0022] The third object of the present invention is to provide the use of the aforementioned compound or its pharmaceutically acceptable salt or the aforementioned pharmaceutical composition in the preparation of a drug for treating loss of interest in depression.
[0023] Furthermore, the pharmaceutically acceptable salt is selected from sodium salt and potassium salt.
[0024] Beneficial effects:
[0025] Currently, commonly used antidepressants in clinical practice generally have shortcomings such as slow onset of action and many side effects. The carboxylic acid and its derivatives provided by the present invention are a new type of antidepressant, which can effectively inhibit the coupling of nNOS-SERT, have the characteristics of rapid onset of action for the core symptom of loss of interest in depression, and can also avoid many side effects of current antidepressants. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 :Identification of XJ series compounds inhibiting nNOS-SERT coupling in cell models;
[0027] HEK293T cells were transfected with nNOS and SERT plasmids at the same time, and HEK293T cells were cultured in vitro and incubated with 10 μM XJ compound. After 3 hours, the co-immunoprecipitation experiment (Co-IP) was used to examine the effect of the compound on nNOS-SERT coupling.
[0028] Among them, a to i represent the effects of XJ-2, XJ-4, XJ-6, XJ-8, XJ-10, XJ-12, XJ-13, XJ-14, and XJ-16 on the inhibition of nNOS-SERT coupling, respectively.
[0029] Figure 2 : The rapid onset of antidepressant effects of XJ-2 compound injected intraperitoneally at physiological levels;
[0030] a is the result of enriched-novel-object exploration test (EET) 2 h after intraperitoneal injection of XJ-2 (10 mg / kg) in mice.
[0031] b is the result of open field test (OFT) 2 hours after intraperitoneal injection of XJ-2 (10 mg / kg) in mice.
[0032] Figure 3 : The antidepressant effect of XJ-2 compound in depression model after long-term intraperitoneal injection;
[0033] a is the result of enriched-novel-object exploration test (EET) in mice 4 weeks after intraperitoneal injection of XJ-2 (10 mg / kg);
[0034] b is the result of tail suspension test (TST) in mice 4 weeks after intraperitoneal injection of XJ-2 (10 mg / kg);
[0035] c is the result of forced swimming test (FST) in mice 4 weeks after intraperitoneal injection of XJ-2 (10 mg / kg);
[0036] d is the result of sucrose preference test (SPT) in mice 4 weeks after intraperitoneal injection of XJ-2 (10 mg / kg). DETAILED DESCRIPTION
[0037] The present invention is further explained below with reference to the examples, but the examples do not limit the present invention in any form.
[0038] Example 1: Synthesis of 2-((1,1,1,3,3,3-hexafluoroprop-2-yl)oxy)acetic acid (XJ-2)
[0039]
[0040] Synthesis of ethyl 2-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)acetate (2)
[0041] Add hexafluoroisopropanol (1.5 g, 29.8 mmol), potassium carbonate (11.81 g, 85.5 mmol), 50 mL of acetone to a dry 250 mL flask, stir at room temperature for 10 min, slowly add ethyl bromoacetate (3.15 mL, 28.5 mmol), and stir at room temperature for 6 h. After the reaction is completed, filter with suction, wash the residue twice with ethyl acetate, collect the filtrate, spin dry the organic solvent, add an appropriate amount of ethyl acetate to dissolve, wash with ice water 3 times, collect the organic layer, and dry it with anhydrous sodium sulfate. Filter, concentrate the filtrate, and chromatograph on a silica gel column (PE: EA = 15: 1) to obtain 2 7 g of a colorless transparent liquid with a yield of 98%. 1 H NMR(400MHz, CDCl3)δ:4.48(hept,J=5.8Hz,1H),4.41(s,2H),4.26(q,J=7.1Hz,2H),1.31(t,J=7.1Hz,3H).MS(ESI,m / z):277.0[M+Na] +
[0042] Synthesis of 2-((1,1,1,3,3,3-hexafluoroprop-2-yl)oxy)acetic acid (XJ-2)
[0043] Add ethyl 2-((1,1,1,3,3,3-hexafluoroprop-2-yl)oxy)acetate (2,4 g, 17.7 mmol), 35 mL of methanol, and 1N sodium hydroxide solution (35 mL, 35 mmol) to a dry 100 mL flask and stir overnight at room temperature. After the reaction is completed, remove the organic solvent by rotary evaporation, add appropriate amount of water to dissolve, adjust the pH to 1 with 2N hydrochloric acid solution, extract three times with ethyl acetate, collect the organic layer, and dry it with anhydrous sodium sulfate. Filter and spin dry the filtrate to obtain 3.5 g of white solid XJ-2 with a yield of 98%. 1 H NMR(400MHz, CDCl3)δ:10.38(s,1H),4.49(s,2H),4.47-4.36(m,1H).MS(ESI,m / z):225.0[MH] - Example 2: Synthesis of 2-((1,1,1-trifluoropropan-2-yl)oxy)acetic acid (XJ-4)
[0044]
[0045] Synthesis of ethyl 2-((1,1,1-trifluoropropan-2-yl)oxy)acetate (4)
[0046] The synthesis method was the same as 2. Starting from compound 1,1,1-trifluoropropan-2-ol (7,3.5 g, 30.7 mmol), 2.04 g of compound 4 was obtained with a yield of 33%. 1 H NMR(400MHz, CDCl3)δ:4.36-4.16(m,4H),3.97-3.83(m,1H),1.42(d,J=6.5Hz,3H),1.30(t,J=7.6Hz,3H).MS(ESI,m / z):223.0[M+Na] +
[0047] Synthesis of 2-((1,1,1-trifluoropropan-2-yl)oxy)acetic acid (XJ-4)
[0048] The synthesis method was the same as compound XJ-2, starting from compound 4 (2.04 g, 10.2 mmol), to obtain compound XJ-41.7 g, with a yield of 97%. 1 H NMR (400MHz, CDCl3) δ: 8.71 (s, 1H), 4.33 (q, J = 17.2Hz, 2H), 3.97-3.86 (m, 1H), 1.42 (d, J = 6.6Hz, 3H). MS (ESI, m / z): 171.0 [MH] -
[0049] Example 3: Synthesis of 2-isopropoxyacetic acid (XJ-6)
[0050]
[0051] Synthesis of 2-isopropoxyacetic acid isopropyl ester (6)
[0052] Add isopropanol (3.5 g, 83.3 mmol) and 50 mL of redistilled tetrahydrofuran to a dry 250 mL flask. Slowly add 60% sodium hydride (3.33 g, 83.3 mmol) under ice bath, stir for 30 min, take ethyl bromoacetate (10.2 mL, 91.6 mmol) and dissolve it in 20 mL of dry tetrahydrofuran, slowly add the above solution, after the addition is complete, stir at room temperature for 5 h. After the reaction is completed, slowly add ice water until no bubbles are generated, add appropriate amount of ethyl acetate to dissolve, wash three times with water, collect the organic layer, and dry it over anhydrous sodium sulfate. Filter, concentrate the filtrate, and chromatograph on a silica gel column (PE:EA=20:1) to obtain 1.05 g of colorless transparent liquid 4, with a yield of 8%. 1 HNMR(400MHz, CDCl3)δ:5.17-5.02(m,1H),4.04(s,2H),3.73-3.56(m,1H),1.24(dd,J1=4.0Hz,J2=8.0Hz,12H).MS(ESI,m / z):183.1[M+Na] +
[0053] Synthesis of 2-isopropoxyacetic acid (XJ-6)
[0054] Add 6 1.05g (6.6mmol), methanol 13mL, 1N sodium hydroxide solution (13mL, 13mmol) to a dry 50mL flask, and stir overnight at room temperature. After the reaction is completed, add appropriate amount of water to dissolve, extract twice with ethyl acetate, collect the water layer, adjust the pH to 1 with 2N hydrochloric acid solution, extract three times with ethyl acetate, collect the organic layer, and dry it with anhydrous sodium sulfate. Filter, and the filtrate is dried to obtain 0.76g of colorless transparent oily liquid XJ-6, with a yield of 98%. 1 H NMR (400MHz, CDCl3) δ: 10.91 (s, 1H), 4.14 (s, 2H), 3.73 (hept, J = 6.1Hz, 1H), 1.23 (d, J = 6.1Hz, 6H). MS (ESI, m / z): 117.1 [MH] - Example 4: Synthesis of 2-(sec-butoxy)acetic acid (XJ-8)
[0055]
[0056] Synthesis of 2-(sec-Butoxy)acetic acid sec-butyl ester (8)
[0057] The synthesis method was the same as compound 6, starting from sec-butyl alcohol (7.5 g, 67.5 mmol) to obtain compound 8 1.25 g, with a yield of 10%. 1 H NMR(400MHz, CDCl3)δ:5.00-4.87(m,1H),4.07(dd,J1=2.6,J2=1.6Hz,2H),3.53-3.36(m,1H),1.70-1.41(m,4H),1. 23(d,J=6.2Hz,3H),1.17(d,J=6.2Hz,3H),0.93(t,J=5.5Hz,3H),0.90(t,J=5.5Hz,3H).MS(ESI,m / z):211.1[M+Na] +
[0058] Synthesis of 2-(sec-Butoxy)acetic acid (XJ-8)
[0059] The synthesis method was the same as that of XJ-6. Starting from compound 8 (1.25 g, 6.6 mmol), 0.69 g of compound XJ-8 was obtained with a yield of 98%. 1 H NMR (400MHz, CDCl3) δ: 9.95 (s, 1H), 4.14 (d, J = 4.0Hz, 2H), 3.56-3.43 (m, 1H), 1.71- 1.42(m,2H),1.19(d,J=6.2Hz,3H),0.93(t,J=7.5Hz,3H).MS(ESI,m / z):131.1[MH] - .
[0060] Example 5: Synthesis of 2-((3-methylbutan-2-yl)oxy)acetic acid (XJ-10)
[0061]
[0062] Synthesis of 2-((3-methylbutan-2-yl)oxy)acetic acid-3-methylbutan-2-ol ester (10)
[0063] The synthesis method is the same as 6, starting from compound 3-methylbutan-2-ol (9.5 g, 54 mmol), to obtain compound 100.88 g, with a yield of 7%. 1 H NMR (400MHz, CDCl3) δ: 4.96-4.73 (m, 1H), 4.07 (dd, J1 = 4.7, J2 = 1.9Hz, 2H), 3.41-3.09 (m, 1H), 1.92-1. 67(m,2H),1.18(d,J=5.6Hz,3H),1.11(d,J=6.3Hz,3H),0.95-0.89(m,12H).MS(ESI,m / z):239.2[M+Na]+
[0064] Synthesis of 2-((3-methylbutan-2-yl)oxy)acetic acid (XJ-10)
[0065] The synthesis method was the same as that of XJ-6. Starting from compound 10 (0.88 g, 4.1 mmol), 0.58 g of compound XJ-10 was obtained with a yield of 97%. 1 H NMR (400MHz, CDCl3) δ: 10.28 (s, 1H), 4.13 (d, J = 6.9Hz, 2H), 3.39-3.26 (m, 1H), 1.93-1.72 (m, 1H) ),1.13(d,J=6.3Hz,3H),0.94(d,J=6.8Hz,3H),0.90(d,J=6.8Hz,3H).MS(ESI,m / z):145.1[MH] -
[0066] Example 6: Synthesis of 2-((1-methylcyclopentyl)oxy)acetic acid (XJ-12)
[0067]
[0068] Synthesis of ethyl 2-((1-methylcyclopentyl)oxy)acetate (12)
[0069] The synthesis method is the same as 2, starting from compound 1-methylcyclopentan-1-ol (11.4 g, 40 mmol), to obtain compound 120.47 g, with a yield of 6%. 1 H NMR (400MHz, CDCl3) δ: 4.21 (q, J = 7.1Hz, 2H), 4.00 (s, 2H), 1.91-1.81 (m, 2H), 1.81-1.71 (m, 2H),1.66-1.54(m,2H),1.49-1.43(m,2H),1.28(t,J=8.0Hz,6H).MS(ESI,m / z):209.1[M+Na] +
[0070] Synthesis of 2-((1-methylcyclopentyl)oxy)acetic acid (XJ-12)
[0071] The synthesis method was the same as that of XJ-2. Starting from compound 12 (0.47 g, 2.3 mmol), 0.38 g of compound 2-((1-methylcyclohexyl)oxy)acetic acid (XJ-12) was obtained with a yield of 96%. 1H NMR(400MHz, CDCl3)δ:9.57(s,1H),4.03(s,2H),1.89-1.81(m,2H),1.81-1.70(m ,2H),1.68-1.60(m,2H),1.58-1.47(m,2H),1.32(s,3H).MS(ESI,m / z):157.1[MH] - .
[0072] Example 7: Synthesis of 2-cyclobutoxyacetic acid (XJ-14)
[0073]
[0074] Synthesis of ethyl 2-cyclobutoxyacetate (14)
[0075] The synthesis method is the same as 2, starting from compound cyclobutanol (13, 4 g, 55.5 mmol), to obtain compound 14 3.15 g, with a yield of 36%. 1 H NMR (400MHz, CDCl3) δ: 4.22 (q, J = 7.1Hz, 2H), 4.07-4.00 (m, 1H), 3.98 (s, 2H), 2.27-2.16 (m, 2H),2.08-1.94(m,2H),1.75-1.42(m,2H),1.29(t,J=7.2Hz,3H).MS(ESI,m / z):181.1[M+Na] +
[0076] Synthesis of 2-cyclobutoxyacetic acid (XJ-14)
[0077] The synthesis method was the same as that of XJ-2. Starting from compound 14 (3.15 g, 20 mmol), 2.46 g of compound XJ-14 was obtained with a yield of 95%. 1 H NMR(400MHz, CDCl3)δ:11.02(s,1H),4.11-4.01(m,3H),2.28-2.18(m,2H),2.07-1.94(m,2H),1.79-1.42(m,2H).MS(ESI,m / z):129.1[MH] - .
[0078] Example 8: Synthesis of 3-methylbutyric acid (XJ-15)
[0079]
[0080] The synthesis method is the same as XJ-2. Starting from compound 3-methylbutyric acid ethyl ester (15, 2.60 g, 20 mmol), compound 3-methylbutyric acid (XJ-15) is obtained with a yield of 90%.1 H NMR (400MHz, CDCl3): δ0.97 (d, J = 5.6Hz, 6H), 1.93-2.21 (m, 3H), 11.62 (s, 1H); 13 C NMR (100MHz, CDCl3): δ22.3, 25.4, 43.2, 180.0.
[0081] Example 9: Synthesis of 3-methylvaleric acid (XJ-16)
[0082]
[0083] The synthesis method was the same as that of XJ-2. Starting from compound 3-methylpentanoic acid ethyl ester (16, 2.88 g, 20 mmol), compound XJ-16 was obtained with a yield of 73%. 1 H NMR (400MHz, CDCl3): δ0.90 (t, 3H, J = 7.4Hz), 0.96 (d, 3H, J = 6.7Hz), 1.19-1.30 (m, 1H), 1.34-1.45 ( m,1H),1.83-1.95(m,1H),2.14(dd,1H,J=8.0,15.0Hz),2.35(dd,1H,J=6.0,15.0Hz),11.64(s,1H); 13 C NMR (400MHz, CDCl3): δ11.4, 19.4, 29.4, 31.9.41.4, 180.4.
[0084] Example 10: Synthesis of 2-(1-cyclopropylethoxy)acetic acid (XJ-17)
[0085]
[0086] Synthesis of 2-(1-cyclopropylethoxy)acetic acid (1-cyclopropyl)ethanol ester (18)
[0087] At -5°C, 2 g (23.2 mmol) of 1-cyclopropylethanol (17), 0.93 g (23.2 mmol) of NaH and 10 ml of dry THF were stirred for 30 min. 4.3 g (25.5 mmol) of ethyl bromoacetate were slowly added, and the reaction was continued at room temperature for 3 h. Water was added to quench the excess NaH, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and then spin-dried. The mixture was purified by silica gel column chromatography (PE:EA=16:1, R f =0.6) to give 0.8 g of (1-cyclopropyl)ethanol 2-(1-cyclopropylethoxy)acetate (18) with a yield of 16.3%. 1H NMR(400MHz,)δ4.26(dq,J=13.1,6.4Hz,1H),4.07(t,J=2.6Hz,2H),2.82(dq,J=7.9,6.2Hz,1H),1.20(dd,J=6.3,1. 0Hz,3H),1.12(d,J=6.2Hz,3H),1.01-0.90(m,1H),0.78-0.67(m,1H),0.51-0.19(m,8H).MS(ESI,m / z):235.2[M+Na] +
[0088] Synthesis of 2-(1-cyclopropylethoxy)acetic acid (XJ-17)
[0089] A mixture of 0.8 g (3.77 mmol) of compound 18, 7.54 ml of 1 mol / L sodium hydroxide and 5 ml of methanol was stirred at room temperature for 1 h. The pH was adjusted to 2-3 with dilute hydrochloric acid, extracted with EtOAc, dried over anhydrous sodium sulfate, and spin-dried. The mixture was purified by silica gel column chromatography (EtOAc: MeOH = 10:1, R f =0.8) to obtain 0.3 g of XJ-17 with a yield of 55.6%. 1 H NMR(400MHz,)δ4.20(dd,J=43.8,16.7Hz,2H),2.87(dq,J=8.7,6.3Hz,1H),1.30(d,J=6.2Hz,3H),0.91-0.79(m,1H),0.63(dddd,J=9 .0,7.8,5.8,4.5Hz,1H),0.55-0.45(m,1H),0.37(dt,J=15.1,4.9Hz,1H),0.07(ddt,J=9.6,5.6,4.8Hz,1H).MS(ESI,m / z):143.1[MH] - .
[0090] Example 11: Synthesis of 2-(1,1,1-trifluoro-2-methylpropane-2-oxy)acetic acid (XJ-18)
[0091]
[0092] Synthesis of ethyl 2-(1,1,1-trifluoro-2-methylpropan-2-oxy)acetate (20)
[0093] At -5°C, a mixture of 1 g (7.81 mmol) of 1,1,1-trifluoro-2-methylpropane-2-ol, 0.19 g (7.81 mmol) of NaH, and 5 ml of dry THF was stirred for 30 min. 1.44 g (8.6 mmol) of ethyl bromoacetate was slowly added, and the mixture was allowed to react at room temperature for 3 h. Water was added to quench the excess NaH, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and then spin-dried. The mixture was purified by silica gel column chromatography (PE:EA=12:1, R f =0.6) to give 0.5 g of 20 with a yield of 21.7%. 1 H NMR (400MHz,) δ4.18 (s, 2H), 4.08 (q, J = 7.1Hz, 2H), 1.29 (t, J = 1.0Hz, 6H), 1.16-1.13 (m, 3H).
[0094] Synthesis of 2-(1,1,1-trifluoro-2-methylpropane-2-oxy)acetic acid (XJ-18)
[0095] A mixture of 0.5 g (2.33 mmol) of compound 20, 4.7 ml of 1 mol / L NaOH aqueous solution and 5 ml of methanol was stirred at room temperature for 1 h. The pH was adjusted to 2-3 with dilute hydrochloric acid, extracted with EtOAc, dried over anhydrous sodium sulfate, and spin-dried. The mixture was purified by silica gel column chromatography (EA:MeOH=10:1, R f =0.8) to obtain 0.15 g of XJ-18 with a yield of 34.9%. 1 H NMR(400MHz)δ:12.63(s,1H),4.08(s,2H),1.29(d,J=0.9Hz,6H).MS(ESI,m / z):185[MH] - .
[0096] Example 12: Synthesis of 2-(1,1,1-trifluorobutane-2-oxy)acetic acid (XJ-19)
[0097]
[0098] Synthesis of 1,1,1-trifluorobutan-2-ol (22)
[0099] At -5℃, take 14ml of 3mol / L ethylmagnesium bromide, under N2 protection, slowly add 2g (14mmol) of ethyl trifluoroacetate, react at room temperature for 3h, and reflux for 1.5h. Under ice-water bath conditions, add saturated ammonium chloride to quench the Grignard reagent, extract with ether, dry with anhydrous sodium sulfate, spin dry at room temperature and directly put into the next step reaction.
[0100] Synthesis of ethyl 2-(1,1,1-trifluorobutane-2-oxy)acetate (23)
[0101] At -5°C, 1 g of the unpurified 1,1,1-trifluorobutan-2-ol (22) from the previous step was dissolved in 5 ml of dry THF, and 0.19 g (7.81 mmol) of NaH was added and stirred for 30 min. 1.44 g (8.6 mmol) of ethyl bromoacetate was slowly added, and the mixture was reacted at room temperature for 3 h. Water was added to quench the excess NaH, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and then spin-dried. The mixture was purified by silica gel column chromatography (PE:EA=12:1, R f =0.8) to give 0.4 g of 23, with a yield of 23.1%. 1 H NMR(400MHz,)δ:4.29(d,J=6.5Hz,1H),4.16-3.96(m,4H),1.60(ddd,J=22.0,10.9,5 .8Hz,2H),1.16(td,J=7.1,1.7Hz,3H),1.00-0.91(m,3H).MS(ESI,m / z):237.1[M+Na] +
[0102] Synthesis of 2-(1,1,1-trifluorobutane-2-oxy)acetic acid (XJ-19)
[0103] Compound 23 0.4 g (1.9 mmol), 1 mol / L sodium hydroxide 3.7 ml and methanol 5 ml were stirred at room temperature for 1 h. The pH was adjusted to 2-3 with dilute hydrochloric acid, extracted with EtOAc, dried over anhydrous sodium sulfate, and spin-dried. Column chromatography on silica gel (EA: MeOH = 10:1, R f =0.8) to obtain 0.14 g of XJ-19 with a yield of 40%. 1 H NMR(400MHz,)δ:12.71(s,1H),4.25-4.12(m,2H),1.62(dddd,J=32.8,21.8,14.1,7.1Hz,2H),1.02-0.90(m,3H).MS(ESI,m / z):185[MH] -
[0104] Example 13: Synthesis of 2-(1,1,1-trifluoropentan-2-oxy)acetic acid (XJ-20)
[0105]
[0106] Synthesis of 1,1,1-trifluoropentan-2-ol (25)
[0107] Synthesis method: 22.2 mol / L propylmagnesium bromide 42 ml and ethyl trifluoroacetate 4 g (28.2 mmol) were reacted to obtain 3.5 g of crude 1,1,1-trifluoropentan-2-ol (25), which was used directly in the next step.
[0108] Synthesis of ethyl 2-(1,1,1-trifluoropentan-2-oxy)acetate (26)
[0109] The synthesis method was the same as 23. Unpurified 25 3.5 g, NaH 0.6 g (24.63 mmol), and ethyl bromoacetate 4.5 g (27.1 mmol) were reacted to obtain ethyl 2-(1,1,1-trifluoropentan-2-oxy)acetate (26) 1 g with a yield of 18%. 1 H NMR (400MHz,) δ4.09 (d, J = 7.0Hz, 5H), 1.63-1.48 (m, 2H), 1.17 (t, J = 7.1Hz, 5H), 0.85 (t, J = 7.4Hz, 3H).
[0110] Synthesis of 2-(1,1,1-trifluoropentan-2-oxy)acetic acid (XJ-20)
[0111] The synthesis method is the same as that of XJ-19, compound 26 1g, 1mol / L NaOH 8.8ml, after reaction treatment, XJ-200.35g is obtained, with a yield of 40%. 1 H NMR(400MHz,)δ12.67(s,1H),4.29-4.01(m,3H),1.61-1.39(m,4H),0.92-0.88(m,3H).MS(ESI,m / z):199.1[MH] - .
[0112] Effect verification example 1: Identification of the inhibition of nNOS-SERT coupling by cell models XJ-2, XJ-4, XJ-6, XJ-8, XJ-10, XJ-12, XJ-13, XJ-14, and XJ-16
[0113] HEK293T cells were transfected with nNOS and SERT plasmids at the same time, and HEK293T cells were cultured in vitro and incubated with 10 μM XJ-series compounds. The control group (Vehicle group) was added with an equal amount of solvent to HEK293T cells cultured in vitro. After 3 hours, immunoprecipitation experiments were used to examine the effects of XJ-series compounds on nNOS-SERT coupling.
[0114] The results are as follows Figure 1 As shown, XJ-2 can significantly reduce the level of nNOS-SERT complex, and compounds XJ-6, XJ-8, XJ-10, and XJ-12 also show a certain ability to inhibit nNOS-SERT coupling.
[0115] Effect verification example 2: Study on the rapid onset of antidepressant effect of XJ-2 compound injected intraperitoneally at physiological levels
[0116] Two hours after intraperitoneal injection of XJ-2 (10 mg / kg) or saline (10 mL / kg), mice were subjected to behavioral tests such as the open field test (OFT) and the enriched-novel-object exploration test (EET). In the EET, the increase in the number of explorations of mice indicated an increase in their interest in exploration.
[0117] Test results see Figure 2 , where Vehicle refers to the group injected with normal saline intraperitoneally, and XJ-2 refers to the group injected with compound XJ-2 intraperitoneally.
[0118] The test results showed that XJ-2 could increase the number of explorations of mice in EET ( Figure 2 a) without affecting spontaneous activity in the open field test ( Figure 2 b) This result proves that XJ-2 exerts a rapid antidepressant effect similar to loss of interest in depression at physiological levels.
[0119] Effect verification example 3: Study on the antidepressant effect of long-term intraperitoneal injection of XJ-2 compound in depression model
[0120] Mice were subjected to CMS depression model for 1 month, and XJ-2 (10 mg / kg) or saline (10 mL / kg) was intraperitoneally injected daily. One month later, the mice were subjected to behavioral tests of enriched-novel-object exploration test (EET), tail suspension test (TST), forced swimming test (FST), and sucrose preference test (SPT). The decrease in the number of explorations in EET indicated that the mice lost interest, the prolonged immobility time in TST and FST indicated that the mice were in despair, and the decrease in the sucrose preference rate in SPT indicated that the mice had anhedonia.
[0121] Test results see Figure 3 Among them, Control+vehicle refers to the group without modeling and with normal saline, CMS+vehicle refers to the CMS model plus normal saline, and CMS+XJ-2 refers to the CMS model plus compound.
[0122] The test results showed that XJ-2 could reverse the EET ( Figure 3 a) The number of explorations is reduced, TST( Figure 3b) and FST( Figure 3 c) The immobility time of CMS model mice was prolonged. The selectivity of sugar water intake was significantly reduced, but intraperitoneal injection of XJ-2 increased the sugar water preference rate of the depression model ( Figure 3 d) These results demonstrate that intraperitoneal injection of XJ-2 can exert an antidepressant effect.
[0123] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Carboxylic acid and its derivatives, characterized in that: Conforms to the following structural formula: X=C,O; n=1~6; R1, R2, and R3 are each independently selected from H, CH3, CF3, Et, n-Pr, i-Pr, cyclopropyl, cyclobutyl, cyclopentyl, Cl, and Br; R4 = H, an alkyl group having 1 to 4 carbon atoms.
2. The carboxylic acid and its derivatives according to claim 1, characterized in that: The structural formula is any of the following compounds:
3. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof.
4. The pharmaceutical composition according to claim 3, characterized in that The pharmaceutically acceptable salt is selected from sodium salt and potassium salt.
5. Use of the compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 3 or 4 in the preparation of a medicament for treating loss of interest due to depression.
6. The use according to claim 5, characterized in that: The pharmaceutically acceptable salt is selected from sodium salt and potassium salt.
Citation Information
Cited By
Derivatives of a class of ether amides or sulfonamides, and methods of making and using the same
CN123003443A
